|
|
|
Procter & Gamble Hygiene Health Care Ltd has posted a net profit of Rs 208.20 million for the quarter ended March 31, 2001 as compared to Rs 173.60 million in the corresponding period last fiscal. Total Income for the quarter ended March 31, 2001 is at Rs 1049.90 million as compared to Rs 1322.50 million in MQ 2000.
Results for the quarter ended March 31 2001 are not exactly comparable with the results of the corresponding quarter ended March 31 2000 because it included sales of shampoos Clearasil and inter company sales adjustment.
Commenting on Q3 performance Mr Bharat Patel Chairman Procter & Gamble Hygiene & Health Care Ltd said. " The company has registered excellent profit growth during the third quarter behind a good performance in its core business viz Feminine and Health Care. The feminine hygiene business continues to grow behind Whisper Ultra, which took a significant price reduction during the quarter to offer consumers even better value on the best product in the category."
|
| Bausch & Lomb Q4 net loss at Rs 7.26 million, FY-01 net loss at Rs 92.08 million
|
Bausch & Lomb India Ltd has posted a net loss of Rs 7.26 million for the quarter ended March 31, 2001 as compared to a net profit of Rs 15.15 million for the quarter ended March 31, 2000. Total Income for the quarter ended March 31, 2001 is at Rs 76.23 million as compared to Rs 124.33 million in MQ 2000.
Total Income for the year ended March 31, 2001 is at Rs 395.20 million as compared to Rs 702 million in FY-00. The net loss for the year ended March 31, 2001 is at Rs 92.08 million as compared to a net profit of Rs 40.36 million for the year ended Mach 31, 2000.
The figures for the quarter ended 31st March, 2001 and the year ended 31st March, 2001 are not comparable to the corresponding previous year figures as the relevant results include financials of Vision Care Business upto 23rd October, 2000.
At the Extraordinary General Meeting held on 27th March, 2001, shareholders approved the change of name of the company form Bausch & Lomb India Limited to RayBan Sun optics India limited and accordingly an application pursuant to section 21 of the Companies Act, 1956 has been made for necessary approvals
|
| TV 18 MQ 2000 net at Rs 13.33 million, FY-01 net at Rs 37.51 million |
Television Eighteen India Ltd has posted a net profit of Rs 13.33 million for the quarter ended March 31, 2001 as compared to Rs 147.90 million in the corresponding period last fiscal. Total Income for the quarter ended March 31, 2001 is at Rs 98.72 million as compared to Rs 119.20 million in the quarter ended March 31, 2000. In the quarter ended March 31, 00 the company had earned an interest of Rs 160.64 million on IPO share application money.
The company has posted a net profit of Rs 37.51 million for the year ended March 31, 2001 on a total income of Rs 197.44 million. The company had posted a net profit of Rs 134.15 million for the previous financial year ended September 30, 2000. In the previous year ended September 30, 00 the company had earned an interest of Rs 160.64 million on IPO share application money.
The Company has decided to change its financial year closing from 30th September to 31st March. Accordingly the financial year ended 31 March 2001 would be for a 6month period from 1 October 2000 to 31 March 2001.
The Current year/period figures are not comparable with those of the previous year, as the current year figures are only for 6 months and whereas previous year figures were for 12 months.
|
| McDowell Q4 net at Rs 25.2 million |
McDowell & Company India Ltd. has posted a net profit of Rs 25.2 million in the quarter ended March 31, 2001. Total income is at Rs 2337.4 million for the quarter ended March 31, 2001.
The Company was incorporated on March 31,1999 as McDowell Spirits Limited with an equity capital of and has changed its name to McDowell & Company Limited as per the Scheme of Amalgamation.
In accordance with the schemes of Amalgamation approved by the respective Honourable high Courts the entire undertaking and business of McDowell & Company Limited Chennai, Udaipur Distillery Company Limited, Udaipur, Serampoire Distillery & Chemical Company Limited Calcutta stand transferred to and vested in the Company w.e.f 01.04.2000 and accordingly the financial results for the quarter ended march 31 2001 include those relating to the aforesaid amalgamating Companies.
The Company is in the process and allotment of equity shares in exchange for the shares held in the erstwhile McDowell & Company Limited, Chennai in the ratio 1:1 as per the Scheme of amalgamation and for the Listing of the Shares with the Stock Exchanges where the shares of the erstwhile McDowell & Company Limited are listed.
|
| Crisil FY-01 net down by 25.17% |
Credit Rating Information Services of India Ltd has posted a net profit of Rs 96.64 million for the year ended March 31, 2001 as compared to Rs 129.16 million posted in the financial year ended March 31, 2000. Total Income for the year ended has increased from Rs 403.30 million in the financial year ended March 31, 2000 to Rs 515.37 million in FY-01.
The Board of Directors has recommended a dividend of Rs 5.50 per share having nominal value of Rs 10 each.
|
| United Breweries Q4 net loss at Rs 128 million, FY-01 net profit at Rs 0.8 million |
United Breweries Ltd has posted a net loss of Rs 128 million for the quarter ended March 31, 2001 as compared to a net profit of Rs 39.70 million in the quarter ended March 31, 00. Total Income for the quarter ended March 31, 2001 is at Rs 978.50 million as compared to Rs 1238.80 million in MQ 2000.
The company has posted a net profit of Rs 0.80 million for the financial year ended March 31, 2001 as compared to Rs 110 million in FY-00. Total Income for the year ended March 31, 2001 is at Rs 3692.20 million as compared to Rs 3702 million in the corresponding period last fiscal.
Interest & Lease Rentals for the quarter ended March 31, 2001 are at Rs 193.10 million as compared to Rs 119 million in MQ 2000.
|
| Glaxo Q1 net down by 27.87% |
Glaxo India Ltd has posted a net profit of Rs 101.70 million for the quarter ended March 31, 2001 as compared to Rs 141 million for the quarter ended March 31, 2000. Total Income for the quarter ended March 31, 2001 is at Rs 1829.90 million as compared to Rs 1771.90 million in the corresponding period last fiscal.
In the Court Convened Meeting of equity shareholders held on April 12, 2001, approval was obtained for the Scheme of Arrangement for the amalgamation of SmithKline Beecham Pharmaceuticals (India) Ltd. with the Company. The above results do not include the financial results of SmithKline Beecham Pharmaceuticals (India) Ltd., pending the final approval of the aforesaid Scheme of Arrangement.
|
| Burroughs Wellcome Q1 net down by 2.61% |
Burroughs Wellcome India Ltd has posted a net profit of Rs 26.1 million for the quarter ended March 31, 2001 as compared to Rs 26.80 million for the quarter ended March 31, 2000. Total Income for the quarter ended March 31, 2001 is at Rs 322.80 million as compared to Rs 303 million in the corresponding period last fiscal.
A significant price reduction in Septran the company's no 1 product in September 2000 has adversely affected both sales and profits for the quarter ended March 31, 2001.
|
| Hero Honda Q4 net down by 9.84%, FY-01 net up by 28.52% |
Hero Honda Motors Ltd has posted a net profit of Rs 561.20 million for the quarter ended March 31, 2001as compared to Rs 622.50 million in the corresponding period last fiscal. Total Income for the quarter ended March 31, 2001 is at Rs 8602.20 million as against Rs 5949.10 million in MQ 2000.
Net profit for the year ended March 31, 2001 is at Rs 2468.70 million as compared to Rs 1920.80 million in the corresponding period last fiscal. Total Income has increased from Rs 22685.60 million in the financial year ended March 31, 2000 to Rs 31929.60 million in the financial year ended March 31, 2001.
The company has sold 1029510 motorcycles during FY-01 as compared to 761623 motorcycles in the financial year ended March 31, 2000. The board has recommended a dividend of 150% ie Rs 3 per equity share of Rs 2 each for the financial year ended March 31, 2001.
|
| BHEL Q4 net up by 38.60%, FY-01 net down by 48.95% |
Bharat Heavy Electricals Ltd has posted a net profit of Rs 4900.30 million for the quarter ended March 31, 2001 as compared to Rs 3535.40 million in the corresponding period last fiscal. Total Income for the quarter ended March 31, 2001 is at Rs 31172 million as compared to Rs 28884.50 million in MQ 2000.
Net profit for the year ended March 31, 2001 is at Rs 3059.90 million as compared to Rs 5994.40 million in the year ended March 31, 2000. Total Income for the year ended March 31, 2001 is at Rs 68077.30 million as compared to Rs 69214.80 million in the corresponding period last fiscal.
|
| Hoechst Marion Q1 net profit up by 59.84% |
Hoechst Marion Roussel Ltd has posted a net profit of Rs 211 million for the quarter ended March 31, 2001 as compared to Rs 132 million for the corresponding period last fiscal. Net Sales have increased from Rs 1028 million in MQ 2000 to Rs 1178 million in the quarter ended March 31, 2001. Other income for the quarter ended March 31, 2001 is at Rs 40 million as compared to Rs 9 million in the corresponding period last fiscal.
Domestic net sales grew by 14.6% over the same quarter last year. Strategic brands grew strongly led by Cardace (96%), Allegra (61%) and Amaryl (66%). Other leading brands such as Rabipur and Daonil continued to grow well and remained market leaders.
Export sales grew by 18%, with good recovery in the CIS and expansion in the new markets of Central Asian Republics.
The enhanced growth of strategic brands and product mix drove operating margins. Operating efficiencies are focused on better allocation of marketing spend, while staff costs have declined 15% over the same period last year. Manufacturing and supply chain efficiencies have contributed significantly to the earnings growth.
|
| Jindal Photo Films Q4 net down by 57.68%, FY-01 net down by 26.72% |
Jindal Photo Films Ltd has posted a net profit of Rs 72.10 million for the quarter ended March 31, 2001 as compared to Rs 170.40 million in the corresponding period last fiscal. Total Income for the quarter ended March 31, 2001 is at Rs 1038 million as compared to Rs 1098.80 million in MQ 2000.
The net profit for the year ended March 31, 2001 is at Rs 362.80 million as compared to Rs 495.10 million in the corresponding period last fiscal. Total Income for the year ended March 31, 2001 is at Rs 3972.30 million as compared to Rs 3807.20 million in the corresponding period last fiscal.
|
| NALCO Q4 net falls 9.66%, FY-01 net up 27.76% |
National Aluminium Company Ltd. has posted a net profit of Rs 1587.1 million in the quarter ended March 31, 2001, as compared to Rs 1757 million in the corresponding period last fiscal. Total income has fallen from Rs 6766.5 million in the quarter ended March 31, 2000 to Rs 6691 million in the quarter ended March 31, 2001.
Net profit for the year ended March 31, 2001 is at Rs 6535.6 million as compared to Rs 5115.3 million in the year ended March 31, 2001. Total Income for the year ended March 31, 2001 is at Rs 24157.6 million as compared to Rs 21155.1 million in FY-00.
|
| Satyam Computer Board approves hike in FII limit from 40% to 49% |
Satyam Computer Services India Ltd has informed BSE that the members of the Board have approved the enhancement of ceiling of investments by FIIs from the existing 40% to 49%. The approval of the shareholders for the enhancement upto the limit permissible under law has already been granted.
In the light of this the company is making an application to the Reserve Bank of India for their approval.
|
| CMC FY-01 net up by 92.56%
|
CMC Ltd has posted a net profit of Rs 244.60 million for the financial year ended March 31, 2001 as compared to Rs 127 million in the financial year ended March 31, 2000. Total Income for the year ended March 31, 2001 is at Rs 5522.13 million as compared to Rs 4687.44 million in the corresponding period last fiscal.
Net profit for the quarter ended March 31, 2001 is at Rs 175.35 million as compared to Rs 43.68 million in the corresponding period last fiscal. Total Income for the quarter ended March 31, 2001 is up by 35.63% as compared to the corresponding period last fiscal. Total Income for the quarter ended March 31, 2001 is at Rs 2324.96 million as compared to Rs 1714.08 million in MQ 2000.
|
| ICICI Bank fixes Book Closure for Dividend
|
| ICICI Bank Ltd. has informed BSE that it has fixed Book Closure from May 23, 2001 to June 06, 2001, for declaring 20% Dividend.
|
| IDBI FY-01 results by June 30, 2001
|
| Industrial Development Bank of India has informed BSE that it will publish audited results within a period of 3 months of the close of the accounting year and therefore will not be publishing quarterly results for the quarter ended March 31, 2001.
|
| UTI Bank FY-01 results on May 05, 2001
|
| UTI Bank Ltd. has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on May 05, 2001 to declare FY-01 results and dividend, if any.
|
| Gujarat Ambuja Q3 PAT up by 31.64% |
Gujarat Ambuja Cements Ltd has posted a profit after tax (profit before extra ordinary items) of Rs 656.90 million for the quarter ended March 31, 2001 as compared to Rs 499 million in the corresponding period last fiscal. Total Income for the quarter ended March 31, 2001 is at Rs 3457.80 million as compared to Rs 2911.80 million posted in MQ 2000.
The Company has commissioned its half million tonne Cement Grinding Unit at Bhatinda, Punjab. With the commissioning of this unit, the company will be able to cater to the South Punjab Market. Work on its 2 million tonne Cement Plant at Chandrapur, Maharashtra is progressing very fast and company expects to complete the cement project on schedule in December 2001.
|
| Malco Q3 net down by 75.82% |
Madras Aluminium Company Ltd net profit has fallen from Rs 132.8 million in the quarter ended March 31, 2000 to Rs 32.1 million in the quarter ended March 31, 01. Net sales for the quarter ended March 31, 2001 are at Rs 721.50 million as compared to Rs 615.20 million in MQ 2000. Other income has fallen from Rs 74 million in the quarter ended March 31, 2001 to Rs 11.50 million in the quarter ended March 31, 2001.
Profits of the quarter ended March 31,2001 are lower than the corresponding quarter ended March 31,2000 on account of decrease in other income (investments), increase in the provision for tax and increase in the cost of raw material (imported coal) and other costs.
|
| Exide Q4 net down by 21.18%, FY-01 net down by 14.99% |
Exide Industries Ltd has posted a net profit of Rs 136.20 million for the quarter ended March 31, 2001 as compared to Rs 172.80 million for the quarter ended March 31, 2000. Total Income for the quarter ended March 31, 2001 is at Rs 2382.10 million as compared to Rs 2214.20 million in the corresponding period last fiscal.
Net profit for the year ended March 31, 2001 is at Rs 415.60 million as compared to Rs 488.90 million in the corresponding period last fiscal. Total Income for the year ended March 31, 2001 is at Rs 7712 million as against Rs 7648.50 million posted in the corresponding period last fiscal.
During the year the company has declared interim dividend for the financial year 2000-2001 at Rs.2.50 per share (25%) at the Board Meeting held on Arpil 5, 2000. In addition, the Board has recommended today (April 27, 2001) a final dividend of Rs. 1.50 per share (15%) making a total of 40% (previous year 35%)
In terms of approval of Board of Directors at the Meeting held on November 24, 2000 the company has acquired 100% shareholding in Chloride Batteries South East Asia Pte Limited, Singapore and 49% shareholding in Associated Battery Manufacturers (Ceylon) Limited, Sri Lanka for an aggregate consideration of Rs.166.90 million.
|
| E Merck Q1 net up by 31.97%, plans to enter therapeutic segment of oral diabetic products |
E Merck India Ltd has posted a net profit of Rs 66.92 million for the quarter ended March 31, 2001 as compared to Rs 50.70 million in the corresponding period last fiscal. Total Income for the quarter ended March 31, 2001 is at Rs 732.26 million as compared to Rs 688.80 million in the quarter ended March 31, 2000.
The company intends to stop dealing in Imaging Products (non ionic radiological X-Ray Contrast Medium). Due to the cessation of this line of business, they also intend to terminate their understanding with Bracco S.P.A, Italy, on the sale and distribution of their products in India effective June 30, 2001. The Company has taken this decision in order to concentrate on other therapeutic segments presently dealt by the Company.
In the first quarter, the Company started marketing the newly acquired product, Livogen, and also launched Acrobat, a modern drug for pain and inflammation. Both these launches have been well received in the market. The newly launched lipid-lowering drug, Trava, is showing an increase in sales every month. The cardiovascular range is being further strengthened with additional products for blood pressure and cardiac failure.
The company proposes to enter into the major therapeutic segment of oral diabetic products in the third quarter. It proposes to launch a basket of 8 products in this category and accordingly all-round preparations are being undertaken towards this purpose.
|
| High Court approves scheme of amalgamation of Jamshedpur Power with Tata Power |
| Tata Power Co Ltd has informed BSE that the High Court of Judicature at Bombay has sanctioned the scheme of amalgamation of Jamshedpur Power Company Ltd with the company. Certified copies of the court's orders are awaited.
|
| Hindalco Industries fixes book closure for dividend |
| Hindalco Industries Ltd. has informed BSE that it has fixed Book Closure from July 17, 2001 to August 01, 2001 for declaring 120% Dividend.
|
| Indian Rayon to buyback upto 15% of equity at Rs 95 per share |
Indian Rayon & Industries Ltd has informed BSE that the company expects to generate cash in excess of requirements. In the company's view there are limited growth opportunities available to meet the company's hurdle rate of return on investment, given the extremely difficult market environment. The Board therefore felt that a share buy-back would be the most tax-efficient way to surplus cash to its shareholders.
Consequently the Board has decided to seek the approval of shareholders for an enabling resolution, so that the company can buy-back upto 15% of the equity shares not exceeding Rs 95 per share. The details of buy back programme will be finalised after obtaining shareholder approval, considering the then prevailing market conditions.
|
| D Chopra appointed as non-Executive chairman of Albright & Wilson |
| Albright & Wilson Chemicals India Ltd. has informed BSE that is has appointed D Chopra as a Director and Non -Executive Chairman of the Company, from April 24, 2001. Prior to this he held senior management positions in several leading multi-national companies in India and abroad.
|
| Borregaard to acquire 9.09% equity of Suven Pharma |
| Suven Pharmaceuticals Ltd. has informed BSE that Borregaard Industries Ltd. has proposed to acquire 0.4 million shares, representing 9.09% of its Company. The aforesaid disclosure is pursuant to Regulation 3 (3) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 1997. The proposed date of acquisition is April 30, 2001. The type of acquisition is by way of preferential allotment and the acquisition price per share is Rs 250 per share.
|
| Hindalco holding in Indal at 74.62% |
| Indian Aluminium Company Ltd. has informed BSE that Hindalco Industries Ltd. holds 53,064,369 equity shares of the Company representing 74.62% of the Company's paid up share capital. The aforesaid is pursuant to Regulation 8 (3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.
|
| Dr Reddy's reiterates its commitment to research |
Dr Reddy's Laboratories Ltd, the Hyderabad based healthcare company today unveiled its new corporate identity and philosophy "Life Research Hope" reinforcing its commitment of bringing hope to life through research. Dr Reddy's new identity also highlights the company's ethos a caring organization that leverages its expertise in research for a healthier life.
Mr Satish Reddy, Managing Director and Chief Operating Officer of Dr Reddy's Laboratories elaborated the company's philosophy of "Life Research Hope". The new identity showcases the company's thought process that envisions a future where Dr Reddy's Laboratories straddles the global markets as an illustrious discovery- based entity powered by innovative R&D. A future that continues to life through meaningful research he said.
|
| Aarti Industries FY-01 net down by 55.2% |
Aarti Industries ltd. has posted a net profit of Rs 159.3 million in the year ended March 31, 2001 as compared to Rs 214.5 million in the corresponding year last fiscal. Total Income for the year ended March 31, 2001 has increased from Rs 2463.5 million in FY-00 to Rs 2855.7 in the financial year ended March 31, 2001.
The Board of Directors has recommended final dividend of 21% for the financial year 2000-2001. The company has paid Interim Dividend of 15%. The Aggregate Dividend for the year is thus 36%.
|
| CyberTech Systems Q4 net down by 90.09%, FY-01 net down by 73.47% |
CyberTech Systems and Software Ltd has posted a net profit of Rs 3.39 million for the quarter ended March 31, 2001 compared to Rs 34.26 million for the corresponding period last fiscal. Total Income has also fallen from Rs 94.34 million in MQ 2000 to Rs 49.84 million in the quarter ended March 31, 2001.
Net profit for the year ended March 31, 2001 is at Rs 53.73 million as compared to Rs 183.54 million in the corresponding period last fiscal. The total income for the year ended March 31, 2001 is at Rs 285.61 million as against Rs 362.47 million in the year ended March 31, 2000.
The companys income during the last quarter was lower because of continued softness in Information Technology market.
During the quarter, the Company has moved an Application with the Honble High Court at Bombay for amalgamation of its 100% wholly owned subsidiary Company viz. Cyber Tech Information and Systems (India) Ltd with the Company.
The High Court of Judicature at Bombay vide their Order dated April 4, 2001 has directed the Company to convene the meeting of Equity Shareholders of the Company on May 18, 2001.
|
| Novartis Board reconstituted |
At its meeting held today April 26, 2001 the Board of Novartis India Ltd announced its reconstitution effective May 01, 2001. New inductions to the Board include Dr R Thompson who succeeds Dr E Schillinger as President and Managing Director of the company. Dr Thompson comes to India from Novartis Corporation New York, where he was Executive Vice President and General Counsel.
The other induction to the Board is Mr A Pyrathon, Head of Pharma Asia Pacific region for the Novartis group Mr Pyrathon replaces Mr G Phillips who retires from the Board.
|
| Knoll Pharma Q1 results on April 30, 2001 |
| A meeting of the Board of Directors of Knoll Pharmaceuticals Ltd has been convened on April 30, 2001 to consider unaudited financial results for the quarter ended March 31, 2001.
|
Money Rapid Information on Stocks & Corporates
Tell us what you think of this report
|
